Jürgen Finke

May 1, 2024 | nature.com | Ali Bazarbachi |Jürgen Finke |Nicolaus Kröger |Martin Bornhauser |Friedrich Stölzel |Peter Dreger | +4 more

AbstractSecond allogeneic stem cell transplantation (alloSCT2) is among the most effective treatments for acute myeloid leukemia (AML) relapse after first alloSCT (alloSCT1). Long-term EBMT registry data were used to provide large scale, up-to-date outcome results and to identify factors for improved outcome.

Mar 18, 2024 | nature.com | Romain Guièze |Johannes Schetelig |Jakob Passweg |Jürgen Finke |Mutlu Arat |Friedrich Stölzel | +7 more

AbstractManagement of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3–63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9–11) and 28 (42.4%) were in complete remission (CR).

Mar 15, 2024 | nature.com | Jürgen Finke |Francis Ayuk |Hartmut Bertz |Eva-Maria Wagner

AbstractATOS is a prospective observational study evaluating the outcome of patients receiving anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation. Primary endpoint was severe GvHD and relapse-free survival (SGRFS). GvHD prophylaxis consisted of ATLG and CSA/ MTX or MMF. Outcome was compared to the ATLG arm of our prospective randomized phase III multicenter trial trial (RCT) [1, 2].

Jan 30, 2024 | nature.com | Meral Beksac |Xavier Poiré |Ali Bazarbachi |Thomas Pabst |Jürgen Finke |Inken Hilgendorf | +3 more

AbstractBortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM patients who received Vel-Mel (n = 292) conditioning were compared with 4,096 Mel200 patients in the same 58 centres.